{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T08:18:23Z","timestamp":1766391503947,"version":"build-2065373602"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.ejphar.2022.174941","type":"journal-article","created":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T18:50:50Z","timestamp":1649271050000},"page":"174941","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Pharmacological characterization of AS2690168, a novel small molecule RANKL signal transduction inhibitor"],"prefix":"10.1016","volume":"924","author":[{"given":"Noriyuki","family":"Morikawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuko","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuaki","family":"Takeshita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuaki","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2022.174941_bib1","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.abb.2008.03.018","article-title":"Functions of RANKL\/RANK\/OPG in bone modeling","volume":"473","author":"Boyce","year":"2008","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.ejphar.2022.174941_bib2","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1089\/adt.2006.4.387","article-title":"High throughput screening identified a substituted imidazole as a novel RANK pathway-selective osteoclastogenesis inhibitor","volume":"4","author":"Chen","year":"2006","journal-title":"Assay Drug Dev. Technol."},{"key":"10.1016\/j.ejphar.2022.174941_bib3","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2022.174941_bib4","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/j.immuni.2015.10.017","article-title":"Inhibition of TNF family cytokine RANKL prevents autoimmune inflammation in central nervous system","volume":"43","author":"Guerrini","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.ejphar.2022.174941_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3177\/jnsv.52.1","article-title":"Comparative therapeutic effects of alendronate and alfacalcidol on cancellous and cortical bone mass and mechanical properties in ovariectomized osteopenic rats","volume":"52","author":"Iwamoto","year":"2006","journal-title":"J. Nutr. Sci. Vitaminol."},{"key":"10.1016\/j.ejphar.2022.174941_bib6","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1538\/expanim.55.357","article-title":"Comparative effects of alendronate and alfacalcidol on cancellous and cortical bone mass and bone mechanical properties in ovariectomized rats","volume":"55","author":"Iwamoto","year":"2006","journal-title":"Exp. Anim. (Tokyo)"},{"key":"10.1016\/j.ejphar.2022.174941_bib7","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2147\/OARRR.S282606","article-title":"Understanding and managing corticosteroid-induced osteoporosis","volume":"13","author":"Kobza","year":"2021","journal-title":"Open Access Rheumatol."},{"key":"10.1016\/j.ejphar.2022.174941_bib8","doi-asserted-by":"crossref","first-page":"5681","DOI":"10.1016\/j.bmcl.2012.06.087","article-title":"Orally available pyridinylpyrimidine derivatives as novel RANKL-induced osteoclastogenesis inhibitors","volume":"22","author":"Miyata","year":"2012","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejphar.2022.174941_bib9","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nrc867","article-title":"Metastasis to bone: causes, consequences and therapeutic opportunities","volume":"2","author":"Mundy","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejphar.2022.174941_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41413-018-0036-5","article-title":"Efficacy of an orally active small-molecule inhibitor of RANKL in bone metastasis","volume":"7","author":"Nakai","year":"2019","journal-title":"Bone Res."},{"key":"10.1016\/j.ejphar.2022.174941_bib11","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1038\/nm.2452","article-title":"Evidence for osteocyte regulation of bone homeostasis through RANKL expression","volume":"17","author":"Nakashima","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejphar.2022.174941_bib12","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.bone.2011.04.001","article-title":"Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys","volume":"49","author":"Ominsky","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.ejphar.2022.174941_bib13","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/JPER.18-0334","article-title":"A novel Bruton's tyrosine kinase inhibitor, acalabrutinib, suppresses osteoclast differentiation and Porphyromonas gingivalis lipopolysaccharide-induced alveolar bone resorption","volume":"90","author":"Pokhrel","year":"2019","journal-title":"J. Priodontol."},{"key":"10.1016\/j.ejphar.2022.174941_bib14","doi-asserted-by":"crossref","first-page":"25103","DOI":"10.1074\/jbc.R109.041087","article-title":"Cellular and molecular mechanisms of bone remodeling","volume":"285","author":"Raggatt","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2022.174941_bib15","doi-asserted-by":"crossref","first-page":"7829","DOI":"10.1073\/pnas.130200197","article-title":"Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression","volume":"97","author":"Shevde","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejphar.2022.174941_bib16","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1002\/jbmr.5650060912","article-title":"Role of colony-stimulating factors in osteoclast development","volume":"6","author":"Takahashi","year":"1991","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.ejphar.2022.174941_bib17","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S1534-5807(02)00369-6","article-title":"Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts","volume":"3","author":"Takayanagi","year":"2002","journal-title":"Dev. Cell"},{"key":"10.1016\/j.ejphar.2022.174941_bib18","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1136\/annrheumdis-2015-208052","volume":"75","author":"Takeuchi","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejphar.2022.174941_bib19","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/14397595.2017.1369491","article-title":"RANKL: a therapeutic target for bone destruction in rheumatoid arthritis","volume":"28","author":"Tanaka","year":"2018","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.ejphar.2022.174941_bib20","first-page":"1","article-title":"Individual and combining effects of anti-RANKL monoclonal antibody and teriparatide in ovariectomized mice","volume":"21","author":"Tokuyama","year":"2015","journal-title":"Bone Rep."},{"key":"10.1016\/j.ejphar.2022.174941_bib21","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1359\/jbmr.090217","article-title":"Evaluation of pharmaceuticals with a novel 50-hour animal model of bone loss","volume":"24","author":"Tomimori","year":"2009","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.ejphar.2022.174941_bib22","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.1021\/jm1016494","article-title":"Discovery of indeno[1,2-c]quinoline derivatives as inhibitors of osteoclastogenesis induced by receptor activator of NF-\u03baB ligand (RANKL)","volume":"54","author":"Tseng","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2022.174941_bib23","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1210\/endo.141.9.7634","article-title":"Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function","volume":"141","author":"Udagawa","year":"2000","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejphar.2022.174941_bib24","doi-asserted-by":"crossref","first-page":"10432","DOI":"10.1002\/jcp.27711","article-title":"AZD8835 inhibits osteoclastogenesis and periodontitis-induced alveolar bone loss in rats","volume":"234","author":"Wang","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.ejphar.2022.174941_bib25","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1038\/nm.2448","article-title":"Matrix-embedded cells control osteoclast formation","volume":"7","author":"Xiong","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejphar.2022.174941_bib26","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1073\/pnas.95.7.3597","article-title":"Osteoclast differentiation factor is a ligand for osteoprotegerin\/osteoclastogenesis-inhibitory factor and is identical to TRANCE\/RANKL","volume":"95","author":"Yasuda","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejphar.2022.174941_bib27","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1002\/jbmr.3655","article-title":"The novel p38 inhibitor, pamapimod, inhibits osteoclastogenesis and counteracts estrogen-dependent bone loss in mice","volume":"34","author":"Zhao","year":"2019","journal-title":"J. Bone Miner. Res."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299922002023?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299922002023?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T23:01:58Z","timestamp":1757977318000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299922002023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":27,"alternative-id":["S0014299922002023"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2022.174941","relation":{},"ISSN":["0014-2999"],"issn-type":[{"type":"print","value":"0014-2999"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological characterization of AS2690168, a novel small molecule RANKL signal transduction inhibitor","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2022.174941","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"174941"}}